These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 2091874)

  • 1. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
    Wolffenbuttel BH; Weber RF; Weeks L; van Koetsveld PM; Verschoor L
    Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Riddle MC; Schneider J
    Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different insulin regimens in elderly patients with NIDDM.
    Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
    Cusi K; Cunningham GR; Comstock JP
    Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
    Simpson HC; Sturley R; Stirling CA; Reckless JP
    Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin on cholesterol synthesis in type II diabetes patients.
    Scoppola A; Testa G; Frontoni S; Maddaloni E; Gambardella S; Menzinger G; Lala A
    Diabetes Care; 1995 Oct; 18(10):1362-9. PubMed ID: 8721938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.
    Diabetes; 1985 Aug; 34(8):793-8. PubMed ID: 2862087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of high fibre diets, basal insulin supplements, and flexible insulin treatment for non-insulin dependent (type II) diabetics poorly controlled with sulphonylureas.
    Scott AR; Attenborough Y; Peacock I; Fletcher E; Jeffcoate WJ; Tattersall RB
    BMJ; 1988 Sep; 297(6650):707-10. PubMed ID: 2852514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
    Fritsche A; Schmülling RM; Häring HU; Stumvoll M
    Acta Diabetol; 2000 Mar; 37(1):13-8. PubMed ID: 10928231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy.
    Paterson KR; Wilson M; Kesson CM; Buchan M; Roberts M; Reith SB; Davidson E
    Diabet Med; 1991 Jan; 8(1):40-3. PubMed ID: 1826243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.